Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3887532 | Kidney International | 2009 | 7 Pages |
Abstract
Posttransplant anemia is a common problem that may hinder patients’ quality of life. It occurs in 12 to 76% of patients, and is most common in the immediate posttransplant period. A variety of factors have been identified that increase the risk of posttransplant anemia, of which the level of renal function is most important. Sirolimus, a mammalian target of rapamycin inhibitor, has been implicated as playing a special role in posttransplant anemia. This review considers anemia associated with sirolimus, including its presentation, mechanisms, and management.
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Steven Fishbane, David J. Cohen, Daniel W. Coyne, Arjang Djamali, Ajay K. Singh, Jay B. Wish,